Brain 17 Vienna

PAge51

11/20/2017 |

Author

Division

Olaf Witt

SIOP LGG 201X

Aims of the Trial

•

Reduction of neurotoxicity

•

Introduce

combined primary endpoint

+ PFS (MRI)

+ neurological function (VABS II)

+ visual function (VA, LogMAR)

•

Biology:

biomarker for prediction of natural course of LGG,

prediction response to chemotherapy/targeted therapy

•

Introduction of

targeted compounds

asap after promising phase

II data